Top Banner
Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ
26

Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Jan 15, 2016

Download

Documents

Marlene Holmes
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Hemostasis, platelets and Blood management

Julie Wegner, PhD, CP

Midwestern University

Glendale, AZ

Page 2: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

None

Page 3: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Why do patients bleed?

• Macrovascular• Microvascular

– Inability to generate thrombin• Insufficient clotting surface (platelets)• Insufficient substrates (clotting factors)• Inhibitors (anticoagulants, antithrombotic agents)

– Clot not strong enough• Insufficient thrombin generation• Weak fibrin-platelet mesh (platelets, fibrinogen)

– Clot vulnerable to lysis

Page 4: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Hemostatic components

Clot location

Substrates for: thrombin generation fibrin formation

Generating environmentProvide substrateProvide protection

Clot formation requirements

PlateletsEndotheliumWBCRBC

Procoagulant factors Intrinsic ExtrinsicAnticoagulant factorsAntithrombotic factors

EndotheliumSubendothelium

Page 5: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Cell-based model

Page 6: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Platelet contributionInitiation and propagation

Serial samplesCancer patients

Correlations: platelet count vs. MA r=0.7 vs. R r=-0.7 vs. r=0.8

Roeloffzen WWH et al. Thrombocytopenia affects plasmatic coagulation as measured bythromboelastography. Blood Coag Fibrinolysis 2010 (in press).

Page 7: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

http://www.integrilin.com/popups/platelet2.html

Platelet cascade

Adhesion

Page 8: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Thrombin generation and

hemostasis

Insufficient clotting surface

Insufficient substrates

Presence of inhibitors

Page 9: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Central role of thrombin

From: Crawley JTB et al. The central role of thrombin. J Thromb Haemost. 2007; 5(Suppl 1): 95-101.

Page 10: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Thrombin generationkinetics

T1 = lag phaseT2 = maximum rate of TGT3 = Peak [thrombin]T4 = Total free thrombin (AUC)

Fibrin cross linkingLateral aggregation

TG = thrombin generation, AUC = area under the curve = endogenous thrombin potential (ETP)

from: Wolberg AS. Blood Rev. 2007.

Page 11: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

From: Vanschoonbeek K, Feijge MAH, van Kampen RJW et al. Initiating and potentiating role of platelets in tissuefactor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogramcharacteristics. J Thromb Haemost. 2004; 2:478-484.

Thrombin generating surfaceThrombin generation and platelet #

Page 12: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Bollinger D et al. Br J Anaesthesiol 2009; 102:793

TG and [substrate]

PPP

(50%)

1. No change in lag time2. Slight decrease rate TG3. Decrease peak TG

Page 13: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

1. Decrease coagulation factors• FV and FVII ~ 28% Dilution• FII and FX ~ 44% Dilution + consumption

2. Thrombin potential – [FX] and [FII]-dependent3. Blood loss vs. thrombin potential (r = -0.75*)

Page 14: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Post-op bleeding:Hemodilution vs. consumption?

• Hemodilution global (cells and factors)

• Consumption → global?– Importance of adequate anticoagulation

• ACT @ 480 sec: clots vs consumption?

Page 15: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Heparin and thrombin generation

From: Tanaka KA, Katori N, Szlam F, Sato N, Kelly AB, Levy JH. Effects of tirofiban on haemostatic activation in vitro. Br J Anaesth.2004; 93:263-269.

Peak thrombin Max. rate thrombin generation Lag time

Page 16: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Reversing heparin effectIs more protamine always good?

• Fine tuning protamine– ‘excess’ protamine:

TG– ‘excess’ protamine:

• Increased time to clot• Decreased clot strength • Enhanced vulnerability

to fibrinolysis

Ni Ainle F et al. Blood 2009; 114:1658

TF

Celite

Nielsen VG. Ann Thorac Surg 2006; 81:1720

Page 17: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Weak clots

Insufficient thrombin generation

Insufficient substrate (fibrinogen)

Weak fibrin-platelet mesh (platelets)

Page 18: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Clot quality and [thrombin]

Wolberg, AS. Thrombin generation and fibrin clot structure. Blood Review 2007; 21: 131- 142

Fiber thickness

Fiber weave

Thick Thin

Loose Tight

Clot strengthLow High

Page 19: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Anesth Analg. 2010 In press

Plateau effect1 g/L

120 x 109/L

Bleeding• Depends on clot strength (MA)

• fibrinogen levels• platelet function

100

Page 20: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Clot strengthFibrinogen vs. platelets

Lang T et al. Anesth Analg 2009; 108:751

Velik-Salchner C et al. JTH 2007; 5:1019

Page 21: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Clot vulnerability to lysis

Importance of clot strength in hemostasis

Page 22: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

http://www.setma.com/article.cfm?ID=330 Holly, J. Cardiometabolic Risk Syndrome Part V: Fibrinolytic Dysfunction

Fibrinolysis

endothelium

contact activation

TAFI Thrombin

I

Page 23: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Clot quality:Clot structure and local [thrombin]

Wolberg, AS. Thrombin generation and fibrin clot structure. Blood Review 2007; 21: 131- 142

Clot strengthLow High

Fibrinolysis vulnerabilityHigh Low

Page 24: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Colloid solutions (HES) do not activate fibrinolysis, but they do makeclots more vulnerable to fibrinolysis

Page 25: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.
Page 26: Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.

Summary

• Variability in hemostasis– One size fits all?– Monitoring

• Thrombin generation – Multiple roles– Rate and peak vs. total thrombin

• Clot structure– Thrombin– Platelets– Fibrinogen

• Clot structure and fibrinolysis